ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Senshio 60 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 60 mg ospemifene.

Excipient with known effect

Each film-coated tablet contains 1.82 mg lactose as monohydrate.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet).
Oval biconvex, white to off-white, film-coated tablets of dimensions 12 mm x 6.45 mm, debossed with “60” on one side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.

4.2 Posology and method of administration

Posology

The recommended dose is one 60 mg tablet once daily with food taken at the same time each day.

If a dose is missed it should be taken with food as soon as the patient remembers. A double dose should not be taken in the same day.

Special populations

Elderly (>65 years old)
No dose adjustment is necessary in patients above the age of 65 years (see section 5.2).

Renal impairment
No dose adjustment is necessary for patients with mild, moderate or severe renal impairment (see section 5.2).
**Hepatic impairment**
No dose adjustment is necessary for patients with mild to moderate hepatic impairment. Ospemifene has not been studied in patients with severe hepatic impairment, therefore Senshio is not recommended for use in such patients (see section 5.2).

**Paediatric population**
There is no relevant use of ospemifene in the paediatric population for the indication of the treatment of moderate to severe symptomatic VVA in post-menopausal women.

**Method of administration**

Oral use.

One tablet should be swallowed whole once daily with food and should be taken at the same time each day.

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Active or past history of venous thromboembolic events (VTEs), including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis.

Unexplained vaginal bleeding.
Patients with suspected breast cancer or patients undergoing active treatment (including adjuvant therapy) for breast cancer (see section 4.4).
Suspected or active sex-hormone dependent malignancy (e.g. endometrial cancer).

Patients with signs or symptoms of endometrial hyperplasia; safety in this patient group has not been studied.

**4.4 Special warnings and precautions for use**

For the treatment of vulvar and vaginal atrophy, ospemifene should only be initiated for symptoms that adversely affect quality of life e.g. dyspareunia and vaginal dryness. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually taking into consideration other menopausal symptoms, effects on uterine and breast tissues, thromboembolic and cerebrovascular risks. Ospemifene should only be continued as long as the benefit outweighs the risk.

**Endometrial findings**

In clinical studies, a mean increase of 0.8 mm in endometrial thickness after 12 months (as assessed by protocol-specified ultrasonography) was observed and there was no increase in vaginal bleeding or spotting in the ospemifene-treated group compared to the placebo-treated group. If bleeding or spotting occurs on therapy, or continues after treatment has been discontinued, this should always be investigated, which may include an endometrial biopsy to exclude endometrial malignancy. The incidence of endometrial hyperplasia was 0.3% (1 case out of 317 biopsies) after 1 year of treatment with an upper 95% confidence limit of 1.74% (see section 5.1). In post-menopausal women who received ospemifene treatment up to 1 year, benign endometrial polyps were reported in 0.4% compared to 0.2% in women who received placebo treatment.

**Venous thromboembolic events (VTEs)**

The risk of VTE (deep vein thrombosis and pulmonary embolism) is increased with other selective estrogen receptor modulators (SERMs). The risk of VTE associated with ospemifene cannot be excluded. Generally recognised risk factors for VTE include advanced age, a family history, severe obesity (BMI>30 kg/m²) and systemic lupus erythematosus (SLE). The risk of VTE is temporarily increased with prolonged immobilisation, major trauma or major surgery. Ospemifene should be discontinued at least 4 to 6 weeks prior to and during prolonged immobilisation (e.g., post-surgical recovery, prolonged bed rest). Treatment should be resumed only after the patient is mobilised.
If VTE develops after initiating therapy, the treatment should be discontinued. Patients should be advised to contact their doctors immediately when they experience a potential thromboembolic symptom (e.g. painful swelling of a leg, sudden pain in the chest, dyspnoea).

Cerebro-vascular events

The risk of cerebrovascular events is possibly increased with other SERMs. The risk of cerebrovascular events associated with ospemifene cannot be excluded. This should be considered when prescribing ospemifene for postmenopausal women with a history of stroke or other significant stroke risk factors.

Pre-existing gynaecological pathology other than signs of vaginal atrophy

There are limited clinical trial data on the use of ospemifene in patients with other gynaecological conditions. It is recommended that any additional pathology be investigated and treated appropriately before starting ospemifene.

Breast cancer

Ospemifene has not been formally studied in women with a prior history of breast cancer. No data are available on its concomitant use with medicinal products used in the treatment of early or advanced breast cancer. Therefore ospemifene should be used for the treatment of VVA only after the treatment of breast cancer, including adjuvant therapy, has been completed.

Hot flushes

Ospemifene may increase the incidence of hot flushes and is not effective in reducing hot flushes associated with oestrogen deficiency. In some asymptomatic patients, hot flushes may occur upon beginning therapy. About 1% of subjects discontinued in the Phase 2/3 clinical programme due to hot flushes.

Co-administration with fluconazole

Caution is recommended when co-administering ospemifene with fluconazole (see section 4.5). If necessary, because of impaired tolerance, ospemifene should be stopped as long as treatment with fluconazole lasts.

Lactose content

Senshio contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Sodium content

Senshio contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

4.5 Interaction with other medicinal products and other forms of interaction

Effects of other medicinal products on ospemifene

Fluconazole, a moderate CYP3A / moderate CYP2C9 / strong CYP2C19 inhibitor, increased the AUC of ospemifene by 2.7-fold. These results suggest that co-administration of ospemifene with any medicinal product that inhibits both CYP3A4 and CYP2C9 activity (e.g. fluconazole) would be expected to increase the exposure of ospemifene in a similar way. Therefore, caution is recommended
when co-administering ospemifene with fluconazole. In case of impaired tolerance of ospemifene, the latter should be stopped as long as treatment with fluconazole lasts.

Ketoconazole, a strong CYP3A4 inhibitor and moderate P-glycoprotein inhibitor, increased the AUC of ospemifene by 1.4-fold. This increase is not considered to be clinically significant given the inherent pharmacokinetic variability of ospemifene. There is therefore no reason to expect that strong CYP3A4 inhibitors would cause a clinically meaningful change in ospemifene exposure. Co-administration of ospemifene with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.

Rifampicin, a strong CYP3A / CYP2C9 enzyme inducer, decreased the AUC of ospemifene by 58%. Therefore, co-administration of ospemifene with strong enzyme inducers like carbamazepine, phenytoin, St John’s wort and rifabutin would be expected to decrease the exposure of ospemifene, which may decrease the clinical effect.

Inhibition of UGT1A3, UGT2B7, UGT1A1, or UGT1A8 may potentially affect the glucuronidation of ospemifene and/or 4-hydroxyospemifene.

In healthy subjects, the absorption of ospemifene is not affected by co-administration of oral omeprazole, a medicinal product that increases gastric pH.

**Effects of ospemifene on other medicinal products**

Interaction studies were performed with probe substrates for CYP2C9 (warfarin), CYP3A4 (midazolam), CYP2C19, and CYP3A4 (omeprazole) and CYP2B6 (bupropion). Ospemifene did not cause a clinically meaningful change in the exposure to the substrates, indicating that ospemifene does not affect those enzyme activities in vivo to a clinically significant extent.

Ospemifene and its major metabolite, 4-hydroxyospemifene, inhibited organic cation transporter (OCT)1 in vitro at clinically relevant concentrations. Therefore, ospemifene may increase concentrations of medicinal products which are substrates of OCT1 (e.g. metformin, acyclovir, ganciclovir and oxaliplatin).

*In vitro*, ospemifene and 4-hydroxyospemifene inhibited glucuronidation mainly via UGT1A3 and UGT1A9 at clinically relevant concentrations. The pharmacokinetics of medicinal products that are mainly metabolised by UGT1A3 and UGT1A9 could be affected when administered concomitantly with ospemifene and co-administration should be made with caution.

The safety of using ospemifene concomitantly with oestrogens or other SERMS, such as tamoxifen, toremifene, bazedoxifene and raloxifene, has not been studied and its concurrent use is not recommended.

Due to its lipophilic nature and absorption characteristics, an interaction between ospemifene and medicinal products like orlistat, cannot be ruled out. Therefore, caution is recommended when ospemifene is combined with orlistat. A clinical monitoring of a decrease in the efficacy of ospemifene should be made.

4.6 **Fertility, pregnancy and lactation**

**Pregnancy**

Senshio is only for use in postmenopausal women and should not be used in women of child-bearing potential. If pregnancy occurs during treatment with ospemifene, ospemifene should be withdrawn immediately.

There are no data on the use of ospemifene in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk in humans is unknown.
Breast-feeding

Senshio is not indicated during breast-feeding.

Fertility

Ospemifene is not indicated for fertile women.

4.7 Effects on ability to drive and use machines

Senshio has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions are hot flushes (7.5%).

Tabulated list of adverse reactions

Adverse reactions are listed below by MedDRA preferred term system organ class and by frequency. Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from available data).

<table>
<thead>
<tr>
<th>MedDRA system organ class</th>
<th>Common</th>
<th>Uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Vulvovaginal candidiasis / mycotic infections</td>
<td>-</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>-</td>
<td>Drug hypersensitivity(^b), Hypersensitivity(^b), Swollen tongue</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache(^c)</td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hot flush</td>
<td>-</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Rash (includes rash erythematosus, rash generalised)</td>
<td>Pruritus</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Muscle spasms</td>
<td>Urticaria</td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td>Vaginal discharge, Genital discharge, Vaginal haemorrhage</td>
<td>Endometrial hypertrophy(^a) (sonographic endometrial thickness)</td>
</tr>
</tbody>
</table>

\(^{a}\) Endometrial hypertrophy is a MedDRA dictionary term that represents sonographic endometrial thickness findings.

\(^{b}\) Hypersensitivity reactions including adverse reactions listed under skin and subcutaneous tissue disorders, swollen tongue, pharyngeal oedema and throat tightening were reported.

\(^{c}\) The frequency of headache reported in the table is that calculated from the Phase 2/3 clinical trials, where the frequency was comparable between 60 mg ospemifene (5.4%) and placebo (5.9%) groups.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
4.9 Overdose
Ospemifene has been administered to subjects in single doses for up to 800 mg day and repeat doses up to 240 mg/day for 7 days and up to 200 mg/day for 12 weeks. There is no specific antidote for ospemifene. In the event of overdose, general supportive measures should be initiated based on the patient’s signs and symptoms.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Sex hormones and modulators of the genital system, selective estrogen receptor modulators, ATC code: G03XC05.

Pharmacodynamic effects
Decreases in oestrogen levels that occur after the menopause lead to VVA, characterised by decreased maturation of vaginal epithelial cells, a progressive decrease in the vascularity of the vaginal tissues, and decreased lubrication. The glycogen content of vaginal epithelial cells also decreases, resulting in reduced colonisation by lactobacilli and increased vaginal pH. These changes result in clinical signs which include vaginal dryness, redness, petechiae, pallor, and friability in the mucosa. In addition, these changes can result in chronic symptoms associated with VVA, the most common of which are vaginal dryness and dyspareunia.

Ospemifene’s biological actions are mediated through the binding of ospemifene and its major metabolite to oestrogen receptors. The relative contribution of the metabolite to the pharmacological effect is estimated to be approximately 40%. This binding results in activation of some oestrogenic pathways (agonism) and blockade of other oestrogenic pathways (antagonism). The biological activity profile in humans is predominantly due to the parent compound.

Nonclinical findings show that ospemifene and its major metabolite have an oestrogen like effect in the vagina increasing the cellular maturation and mucification of the vaginal epithelium. In the mammary gland, they have a predominantly oestrogen antagonist effect. In bone, ospemifene has agonist-like activity. In the uterus ospemifene and its major metabolite have weak partial agonist/antagonist effects. These non-clinical findings are consistent with findings from clinical trials, in which ospemifene demonstrated benefits on vaginal physiology without apparent oestrogen-like effects on breast tissue (see subheading Clinical safety).

Clinical efficacy and safety
The clinical efficacy and safety of ospemifene was determined primarily from two multi-centre, placebo-controlled trials of 12 weeks duration (trials 1 and 2) and a third long-term safety trial of 52 weeks duration (trial 3) in post-menopausal patients with VVA. In those trials, a total of 1,102 subjects received 60 mg of ospemifene and 787 subjects received placebo. In the two 12 weeks studies (trials 1 and 2), 739 patients received ospemifene and 724 patients received placebo. All patients received non-hormonal vaginal lubricant for use as needed; therefore, the effects on efficacy endpoints in the ospemifene treatment group were in addition to those achieved with lubricant use alone. The study population consisted of generally healthy post-menopausal women between 41 to 80 years of age (mean age = 59 years), who at baseline had ≤ 5.0% superficial cells in the vaginal smear, a vaginal pH >5.0 and were required to have at least one moderate or severe VVA symptom, where patients had to choose the symptom that was the most bothersome (MBS). There were four co-primary endpoints for which change from baseline was assessed: percentage parabasal cells and superficial cells in the vaginal smear, vaginal pH, and MBS of VVA (dryness or dyspareunia).
The long-term study (trial 3) was a 52-week, randomised, double-blind, placebo-controlled safety and efficacy study in 426 postmenopausal women with an intact uterus. Of the 426 subjects enrolled in the study, 363 (85.2%) subjects were randomised to once-daily oral doses of ospemifene 60 mg and 63 (14.8%) subjects were randomised to placebo. The mean age of participants was 61.7 years in the ospemifene 60 mg group and 62.9 years in the placebo group.

**Clinical efficacy**

**Physiological responses (objective measures)**
Ospemifene (OSP) improved post-menopausal physiologic changes. In two separate 12 week pivotal trials (trials 1 and 2), ospemifene was associated with a statistically significant mean decrease from baseline in the percentage of parabasal cells and vaginal pH and a statistically significant mean increase from baseline in the percentage of superficial cells, compared with placebo (P<0.001 for each parameter) at weeks 4 and 12. This improvement in objective measures (superficial and parabasal cells and pH) were sustained in ospemifene treated women in a long-term study of up to 52 weeks. The magnitude of effect was similar in all three trials.

**Symptoms (subjective measures)**
The most bothersome symptom (MBS) was assessed at baseline, 4 and 12 weeks with the severity scored as follows: None=0, Mild=1, Moderate=2, Severe=3. Table 1 shows the mean change in severity score in MBS after 12 weeks with the associated statistical testing for the difference vs. placebo for trials 1 and 2.

**Table 1: Primary efficacy analysis - change from baseline to week 12 in most bothersome symptom (ITT, LOCF)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Dryness</th>
<th>Dyspareunia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60 mg OSP</td>
<td>Placebo</td>
</tr>
<tr>
<td>Trial 1</td>
<td>-1.26</td>
<td>-0.84</td>
</tr>
<tr>
<td>Trial 2</td>
<td>-1.3</td>
<td>-1.1</td>
</tr>
</tbody>
</table>

Table 2 shows the percentage of subjects who reported a change in their MBS at week 12.
“Improvement” was defined as a reduction in the severity score of 1 or more.
“Relief” was defined as no or only mild symptoms at week 12.
“Substantial improvement” was restricted to patients who had moderate or severe MBS at baseline and changed from severe to mild or severe or moderate to none.

**Table 2: Percentage of patients with improvement, relief or substantial improvement of MBS after 12 weeks on ospemifene vs. placebo (ITT, LOCF)**

<table>
<thead>
<tr>
<th>Improvement</th>
<th>Relief</th>
<th>Substantial improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>60 mg OSP</td>
<td>Placebo</td>
</tr>
<tr>
<td>Trial 1</td>
<td>Dryness</td>
<td>74.6%</td>
</tr>
<tr>
<td></td>
<td>P=0.0101</td>
<td>P=0.0140</td>
</tr>
<tr>
<td>Trial 2</td>
<td>Dryness</td>
<td>70.6%</td>
</tr>
<tr>
<td></td>
<td>P=0.7134</td>
<td>P=0.1380</td>
</tr>
<tr>
<td>Trial 1</td>
<td>Dyspareunia</td>
<td>68.3%</td>
</tr>
<tr>
<td></td>
<td>P=0.0255</td>
<td>P=0.0205</td>
</tr>
<tr>
<td>Trial 2</td>
<td>Dyspareunia</td>
<td>79.9%</td>
</tr>
<tr>
<td></td>
<td>P=0.0000</td>
<td>P=0.0001</td>
</tr>
</tbody>
</table>

A trend was observed in both trials in the improvement of MBS from baseline to week 4 in favour of ospemifene compared to placebo, although the difference was not statistically significant.
**Clinical Safety**

Across all placebo-controlled clinical trials of ospemifene, deep vein thrombosis occurred at a frequency of approximately 3.65 cases per 1,000 patient years on 60 mg ospemifene (95% confidence interval of 0.44 to 13.19) versus 3.66 cases per 1,000 patient years for placebo (95% confidence interval of 0.09 to 20.41; relative risk is 1.0).

Endometrial safety in women was assessed at baseline and 12 weeks in the two 12-week phase III studies (trials 1 and 2: ospemifene, n=302; placebo, n= 301). For subjects completing the trial 1 extension study (ospemifene, n=41; placebo, n= 18) and for subjects in the long-term 52-week safety study (trial 3: ospemifene, n=276; placebo, n=46), endometrial safety was assessed by endometrial biopsy at baseline and at 12 months. In total, there were 317 subjects on ospemifene and 64 subjects on placebo who had a baseline as well as a week 52 biopsy. No cases of endometrial hyperplasia were reported at either time point.

There was a single subject (0.3%) who developed endometrial hyperplasia in the ospemifene group (simple hyperplasia without atypia) 88 days after the last dose of study drug. No subjects in either group developed endometrial cancer or breast cancer during the trials. Across all placebo controlled clinical trials, there was no significant difference in breast related adverse events between ospemifene and placebo. The incidence of abnormal, but not clinically significant, findings on breast palpation and mammography decreased in the ospemifene 60 mg population during the 1-year study (trial 3) from 1.6% to 0.6% and from 11.8% to 8.1% respectively. In contrast, abnormal, not clinically significant, findings on mammography increased in the placebo population from 6.5% to 8.3%. There were no abnormal breast palpation findings in the placebo group at baseline or at study end.

**Paediatric population**

The European Medicines Agency has waived the obligation to submit the results of studies with ospemifene in all subsets of the paediatric population in VVA (see section 4.2 for information on paediatric use).

### 5.2 Pharmacokinetic properties

**Absorption**

Ospemifene is absorbed rapidly after oral administration, with a T\textsubscript{max} of approximately 3 - 4 hours post-dose in the fed state. The absolute bioavailability of ospemifene has not been established. Mean ospemifene C\textsubscript{max} and AUC\textsubscript{0-24hr} were 785 ng/mL and 5,448 ng•hr/mL, respectively, after repeat doses of 60 mg ospemifene once daily in the fed state.

When ospemifene is administered with a high fat meal, the C\textsubscript{max} and AUC are 2.5-fold and 1.9-fold higher, respectively, with lower variability relative to the fasting state. A low fat meal resulted in approximately a two-fold increase in exposure of ospemifene and a high fat meal resulted in approximately a three-fold increase in exposure of ospemifene in two food effect studies with tablet formulations different from the commercial formulation. It is recommended that ospemifene should be taken with food at the same time each day.

**Distribution**

Ospemifene and 4-hydroxyospemifene are highly (both >99%) bound to serum proteins. Plasma/blood cell partitioning of [\textsuperscript{14}C]-Ospemifene (< 3%) and [\textsuperscript{14}C]-4-hydroxyospemifene (< 2%) is low. The apparent volume of distribution is 448 l.

**Biotransformation**

Ospemifene and its major metabolite, 4-hydroxyospemifene, are metabolised by multiple metabolic pathways, the main enzymes involved are UGT1A3, UGT2B7, UGT1A1, and UGT1A8, and CYP2C9,
CYP3A4 and CYP2C19. The major metabolite, 4-hydroxyospemifene, was seen to undergo formation rate-limited elimination (with $t_{1/2}$ similar to the parent compound) in a human mass balance study. The principal radioactive component in both plasma and faeces was ospemifene and the main metabolite 4-hydroxyospemifene. Ospemifene and 4-hydroxyospemifene accounted for approximately 20% and 14% of the total radioactivity in serum, respectively. The apparent total body clearance is 9.16 l/hr using a population approach.

In vitro, ospemifene and 4-hydroxyospemifene did not inhibit or induce the activity of CYP450 enzymes at clinically relevant concentrations. In vitro, ospemifene and 4-hydroxyospemifene inhibited glucuronidation via UGT1A3 and UGT1A9 at clinically relevant concentrations. In in vitro studies ospemifene is a weak inhibitor for CYP2B6, CYP2C9, CYP2C19, CYP2C8 and CYP2D6. Furthermore in vitro studies have shown that ospemifene is a weak inducer for CYP2B6 and CYP3A4. In in vitro studies, ospemifene and 4-hydroxyospemifene did not inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT2, organic anion transporter (OAT)1, OAT3, or bile salt export pump (BSEP) transporters at clinically relevant concentrations. It is unknown if ospemifene is a substrate for BCRP in the intestine. Therefore care should be taken if ospemifene is administered with a BCRP inhibitor.

Elimination

The apparent terminal half-life of ospemifene in post-menopausal women is approximately 25 hours. Following oral administration of $[3^3\text{-H}]$-ospemifene in the fasted state, approximately 75% and 7% of the dose was excreted in faeces and urine respectively. Less than 0.2% of the ospemifene dose was excreted unchanged in urine. Following a single oral administration of 60 mg ospemifene in the fed state, 17.9%, 10.0% and 1.4% of the administered dose was excreted in faeces as ospemifene, 4-hydroxyospemifene and 4'-hydroxyospemifene, respectively. The fate of remaining fraction is unknown but can probably be explained by formation of glucuronide metabolites.

Linearity/non-linearity

Ospemifene exhibits linear pharmacokinetics in the fed state within the dose range of 60 mg to 240 mg.

Pharmacokinetics in subpopulations

Age

No clinically meaningful differences in ospemifene pharmacokinetics have been observed over the age range studied (40-80) years of age. No dose adjustment is necessary in elderly patients.

Paediatric population

Pharmacokinetic studies have not been performed with ospemifene in the paediatric population.

Renal impairment

Renal clearance of unchanged active substance is a minor pathway of elimination, less than 0.2% of the ospemifene dose is excreted unchanged in urine. In patients with severe renal impairment the ospemifene exposure was increased by approximately 20%, when compared to healthy matched subjects. No clinically important pharmacokinetic differences between subjects with severe renal impairment and healthy subjects were observed. This difference is not considered clinically relevant and no dose adjustment is necessary in patients with renal impairment.

Hepatic impairment

Ospemifene is primarily metabolised by the liver. The pharmacokinetics of ospemifene is only mildly affected by mild and moderate hepatic impairment (Child Pugh scores 5-9) when compared to healthy matched controls. In patients with moderate hepatic impairment the exposure of ospemifene and 4-hydroxyospemifene was approximately 30% and 70% higher. These changes in pharmacokinetics of ospemifene by moderate hepatic impairment are not considered to be clinically significant in consideration of inherent pharmacokinetic variability of ospemifene. No dose adjustment is necessary.
in patients with mild or moderate hepatic impairment. The pharmacokinetics of ospemifene has not been evaluated in patients with severe hepatic impairment (Child-Pugh Class score >9).

Other special populations

Gender
Senshio is indicated for use only in postmenopausal women.

Race
Pharmacokinetic differences due to race have been studied in 1,091 postmenopausal women, including 93.1% White, 3.9% Black, 1.8% Asian and 1.1% other in VVA trials. There were no discernible differences in ospemifene plasma concentrations among these groups; however, the influence of race cannot be conclusively determined.

CYP2C9 poor metabolisers

Both CYP2C9 and CYP3A4 are involved in the metabolism of ospemifene. Co-administration of ketoconazole, a strong CYP3A4 inhibitor, increased the AUC of ospemifene by 1.4-fold. In CYP2C9 poor metabolizers, co-administration of CYP3A4 inhibitors may increase systemic concentration of ospemifene to a larger extent. Therefore, co-administration of ospemifene with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known, or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.

5.3 Preclinical safety data

In repeat dose toxicity studies in mouse, rat, dog and the cynomolgus monkey main target organs of toxicity were the ovary, uterus and the liver. Ospamifene-related changes included ovarian follicular cysts, endometrial stromal atrophy and endometrial hypertrophy/hyperplasia which are consistent with the pharmacologic activity of ospemifene in the intact, normally cycling animal. In the liver hepatocyte hypertrophy or increased glycogen storage, increase in alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were observed. Overall, these findings are characteristic for an induction of CYP isoenzymes and are regarded as adaptive responses without any histopathological signs of liver injury. No changes in blood biochemical parameters such as ALT or ALP were determined in postmenopausal women treated with Ospemifene in clinical studies. Taken together, the liver changes observed in experimental animals in repeat dose toxicity studies are regarded as adaptive changes due to enzyme induction and given the lack of any clinical signs are unlikely to represent a safety concern for humans.

Ospamifene was not mutagenic or clastogenic when evaluated in a standard battery of in vitro and in vivo tests.

In a 2-year carcinogenicity study in female mice, ospemifene caused treatment related increases in neoplastic findings in the adrenal gland and ovary. Systemic exposure (AUC) at these doses was 2.1-, 4.0- and 4.7-times the AUC in postmenopausal woman administered 60 mg/day. In the adrenal gland, there was an increased incidence of adrenal subcapsular cell and adrenal cortical tumours in animals dosed at high dose. In the ovary, there was an increase in sex-cord stromal tumours, tubulostromal tumours, granulosa cell tumours and luteomas in all treatment groups.

In a 2-year carcinogenicity study in rats, a clear increase in mostly benign thymic tumours was recorded at all ospemifene dose levels. This effect was likely due to the anti-oestrogenic effect of ospemifene in this target tissue, which was attenuating the physiological thymic involution (atrophy) process induced by oestrogens starting during puberty. In the liver, an increase in hepatocellular tumours were recorded at all ospemifene dose levels. Systemic exposure (AUC) at the administered doses was 0.3-, 1.0- and 1.2-times the AUC in postmenopausal woman administered 60 mg/day.
Overall, tumour development in these studies is believed to be the result of rodent specific hormonal mechanisms when treated during their reproductive lives; these findings are unlikely to have any clinical relevance in postmenopausal women.

Ospemifene was not teratogenic in rats or rabbits. In a two-generation reproductive study on pre-and postnatal development ospemifene induced an increased post-implantation loss, an increased number of dead pups at birth as well as an increased incidence of postnatal loss of pups in the F1 generation. In the F0 maternal generation, a significant prolonged gestation was observed. However, all exposures were far below the intended human exposure. The reproductive effects observed are considered to be related to oestrogen receptor activity of ospemifene. Fertility studies were not conducted.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

**Tablet core:**

Colloidal silicon dioxide (E 551)
Magnesium stearate (E 578)
Mannitol (E 421)
Microcrystalline cellulose (E 460)
Povidone (E 1201)
Pregelatinised starch (maize)
Sodium starch glycolate (type A)

**Film coating:**

Hypromellose (E 464)
Lactose monohydrate
Titanium dioxide (E 171)
Triacetin (E 1518)
Macrogols (E 1521)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

5 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PVC/PVdC-Aluminium blister. Pack sizes of 7, 28 or 84 film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER

Shionogi B.V.
Kingsfordweg 151
1043GR Amsterdam
Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/978/001
EU/1/14/978/002
EU/1/14/978/003

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 15 January 2015

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release
Shionogi B.V.
Kingsfordweg 151
1043GR Amsterdam
Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

- Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

<table>
<thead>
<tr>
<th>Description</th>
<th>Due date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-interventional post-authorisation safety study (PASS): An observational retrospective cohort study of ospemifene to assess the incidence of venous thromboembolism and other safety concerns as agreed in the risk management plan, in VVA patients treated with ospemifene compared to 1) patients newly prescribed SERMs for oestrogen-deficiency conditions or breast cancer prevention, and 2) the incidence in untreated VVA patients.</td>
<td>28 Feb 2021</td>
</tr>
</tbody>
</table>
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### CARTON

1. **NAME OF THE MEDICINAL PRODUCT**
   
   Senshio 60 mg film-coated tablets
   ospemifene

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**
   
   Each film-coated tablet contains 60 mg ospemifene.

3. **LIST OF EXCIPIENTS**
   
   Contains lactose. See leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**
   
   - 7 film-coated tablets
   - 28 film-coated tablets
   - 84 film-coated tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**
   
   Read the package leaflet before use.
   Oral use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**
   
   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Shionogi B.V.
Kingsfordweg 151
1043GR Amsterdam
Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/14/978/001  7 film-coated tablets
EU/1/14/978/002  28 film-coated tablets
EU/1/14/978/003  84 film-coated tablets

13. BATCH NUMBER

BN

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Senshio

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA

PC
SN
NN
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLISTER</td>
</tr>
</tbody>
</table>

| 1. NAME OF THE MEDICINAL PRODUCT                  |
| Senshio 60 mg tablets                             |
| ospemifene                                        |

| 2. NAME OF THE MARKETING AUTHORISATION HOLDER     |
| Shionogi                                          |

| 3. EXPIRY DATE                                    |
| EXP                                               |

| 4. BATCH NUMBER                                   |
| BN                                                |

| 5. OTHER                                          |
| Mon.                                              |
| Tue.                                              |
| Wed.                                              |
| Thu.                                              |
| Fri.                                              |
| Sat.                                              |
| Sun.                                              |
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Senshio 60 mg film-coated tablets
ospemifene

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Senshio is and what it is used for
2. What you need to know before you take Senshio
3. How to take Senshio
4. Possible side effects
5. How to store Senshio
6. Contents of the pack and other information

1. What Senshio is and what it is used for

Senshio contains the active substance ospemifene. Ospemifene belongs to a group of medicines that do not contain hormones called Selective Estrogen Receptor Modulators (SERMs).

**Senshio is used to** treat women with moderate to severe post-menopausal symptoms in and outside the vagina, such as itching, dryness, burning and pain during sex (dyspareunia) if local oestrogen therapy is not suitable. This is known as vulvar and vaginal atrophy. It is caused by a lowering in the levels of the female hormone oestrogen in your body. When this happens, the vaginal walls can become thinner. This happens naturally after menopause (post-menopause).

**Senshio works** in a similar way to some of the helpful effects of oestrogen, helping to improve these symptoms and the underlying causes of vulvar and vaginal atrophy.

2. What you need to know before you take Senshio

**Do not take Senshio**
- If you are allergic to ospemifene or any of the other ingredients of this medicine (listed in section 6).
- If you have or have ever had a **blood clot in a vein** (thrombosis), for example, in your legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis).
- If you have **unexplained vaginal bleeding**.
- If your doctor thinks you might have **breast cancer** or you are being treated for breast cancer.
- If your doctor thinks you might have or you are being treated for **cancer which is sensitive to oestrogens**, such as cancer of the womb.
- If you have **excessive thickening of the womb lining**, such as endometrial hyperplasia.
Warnings and precautions
Once you have started on Senshio you should see your doctor for regular check-ups (at least once a year). At these check-ups, discuss with your doctor the benefits and risks of continuing with Senshio.

Talk to your doctor or pharmacist before taking Senshio if any of the following apply to you.
- Any of your close relatives has ever had a blood clot in the leg, lung or other organ.
- You are seriously overweight (BMI >30 kg/m\(^2\)).
- You have an autoimmune condition called systemic lupus erythematosus (SLE).
- If you have had a stroke (a cerebrovascular accident), or if your doctor has told you that you are at high risk of having one.
- If you are suffering from any gynaecological illness other than vulvar and vaginal atrophy.
- If you have had breast cancer.

While taking Senshio:
- If you are unable to walk for a long time or are sitting for a long time in the same position because of major surgery, injury or illness, it may prevent good blood circulation and may temporarily increase your risk of blood clots. You should therefore speak to your doctor immediately. Your doctor may recommend that you stop treatment at least 4 to 6 weeks prior to major surgery or during a long period of bed rest e.g. injury or illness. Treatment with Senshio can be restarted as soon as you regain your mobility and in consultation with your doctor.
- If any vaginal bleeding occurs while taking Senshio or soon after you have stopped taking it, you should speak to your doctor.
- If you experience signs of a blood clot, such as painful swelling and redness of the legs, sudden chest pain, difficulty in breathing or a stroke while taking Senshio, stop taking Senshio and see a doctor immediately.

Children and adolescents
Do not give this medicine to children or adolescents. This medicine is only intended for use in post-menopausal women.

Other medicines and Senshio
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Do not take Senshio with any of these medicines:
- Oestrogens.
- Any other medicine belonging to the group called SERMs, such as tamoxifen, toremifene, bazedoxifene and raloxifene.

Talk to your doctor before taking Senshio with:
- Fluconazole (an oral medicine used to treat fungal infections) as this may increase the amount of ospemifene in your blood. Your doctor may consider stopping treatment with Senshio while you are taking fluconazole.
- Any of the following medicines, which may lead to a reduced effect of Senshio:
  o Rifampicin and rifabutin commonly used to treat tuberculosis.
  o Carbamazepine and phenytoin used to treat convulsions/seizures (anticonvulsants).
  o St John’s wort, a herbal medicine sometimes used to treat depression.
  o Orlistat sometimes used to treat obesity.
- Any of the following medicines, as their concentrations may be increased while taking Senshio:
  o Metformin used to treat Type II diabetes.
  o Aciclovir used to treat cold sores and genital herpes.
  o Ganciclovir used to treat infections caused by a virus called cytomegalovirus.
  o Oxaliplatin, an anti-cancer medicine for advanced (metastatic) cancer of the large bowel (colon) or back passage (rectum).
**Pregnancy, breast-feeding and fertility**
Senshio is for use only in postmenopausal women. It must not be taken by women who are pregnant, who could still have a baby or are breast-feeding. This is because there are no data on the use of Senshio in pregnant or pre-menopausal women or those who are breast-feeding.

**Tell your doctor immediately if you become pregnant while taking Senshio;** treatment should be stopped immediately.

**Driving and using machines**
Senshio has no known or very little influence on the ability to drive and use machines.

**Senshio contains lactose**
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

**Senshio contains sodium**
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

3. **How to take Senshio**
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is one tablet taken orally at the same time each day. Senshio should be taken with food. The tablets should be swallowed whole with food.

Senshio must be taken every day for as long as your doctor tells you to.

**Patients with liver disease**
This medicine is not recommended if you have severely reduced liver function.

**If you take more Senshio than you should**
If you take more tablets than you should, tell your doctor or pharmacist.

**If you forget to take Senshio**
If you forget to take a tablet you should take the missed tablet (with food) as soon as you remember within the same day. Do not take two tablets in one day to make up for a forgotten tablet.

**If you stop using Senshio**
You will not benefit from the effects of Senshio if you stop using it without talking to your doctor. Your doctor will explain the effects of stopping treatment and will also discuss other possibilities for treatment with you.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. **Possible side effects**
Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Common side effects** (may affect up to 1 in 10 people):
- An infection of the genitals caused by a fungus (thrush)
- Hot flushes
- Muscle cramps
- Vaginal or genital discharge
- Rash
- Headache
- Vaginal bleeding

**Uncommon side effects** (may affect up to 1 in 100 people):
- Thickening of the womb lining (endometrium) as seen on ultrasound scan (endometrial hypertrophy).
- An allergic reaction. Symptoms of an allergic reaction may include rash, itchy skin, raised patches on your skin (urticaria), swelling of the tongue and throat that may cause difficulty in breathing or swallowing.

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Senshio**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Senshio contains**
- The active substance is ospemifene. Each film-coated tablet contains 60 mg ospemifene.
- The other ingredients are:
  - **Tablet core**: Colloidal silicon dioxide (E 551), magnesium stearate (E 578), mannitol (E 421), microcrystalline cellulose (E 460), povidone (E 1201), pregelatinised starch (maize), sodium starch glycolate (type A).
  - **Film coating**: Hypromellose (E 464), lactose monohydrate, titanium dioxide (E 171), triacetin (E 1518), polyethylene glycol (E 1521).

**What Senshio looks like and contents of the pack**
Senshio tablets are oval biconvex, white to off-white, film-coated tablets (approximately 12 mm long by 6.45 mm wide) debossed with “60” on one side. They are packed in blisters and are available in pack sizes of 7, 28 or 84 film-coated tablets.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder**
Shionogi B.V.
Kingsfordweg 151
1043GR Amsterdam
Netherlands
Manufacturer
Shionogi B.V.
Kingsfordweg 151
1043GR Amsterdam
Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

AT, BE, BG, CY, CZ, DK, EE, IE, EL, FI, FR, HR, HU, IE, IS, LT, LU, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK
Shionogi B.V.
Tel/Tel./Tél./Tlf/Puh/Sími/Tηλ.: +31 (0)20 703 8327
contact@shionogi.eu

DE
Shionogi GmbH
Tel: +49 (0)89 2109 3049
kontakt@shionogi.eu

ES
Shionogi SLU
Tel: +34 911 239 258
contacta@shionogi.eu

IT
Shionogi Srl
Tel: +39 06 94 805 118
contattaci@shionogi.eu

UK
Shionogi B.V.
Tel +44 (0)20 3053 4190
contact@shionogi.eu

This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: